We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.1B
AUM Growth
-$787M
Cap. Flow
+$233M
Cap. Flow %
2.56%
Top 10 Hldgs %
30.12%
Holding
189
New
31
Increased
28
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$200M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
BIIB icon
Biogen
BIIB
+$54.7M
4
HCA icon
HCA Healthcare
HCA
+$47.4M
5
MREO
Mereo BioPharma
MREO
+$45.7M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$78.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$58.9M
3
NTRA icon
Natera
NTRA
+$55.6M
4
ELV icon
Elevance Health
ELV
+$48.9M
5
BSX icon
Boston Scientific
BSX
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIBN icon
51
SI-BONE Inc
SIBN
$797M
$48.2M 0.53%
2,248,000
+942,700
+72% +$23.9M
HCA icon
52
HCA Healthcare
HCA
$90.4B
$47M 0.52%
+193,800
New +$47.4M
ERAS icon
53
Erasca
ERAS
$6.14B
$46M 0.51%
+2,167,341
New +$44.7M
SEM
54
DELISTED
Select Medical
SEM
$46M 0.51%
2,359,162
– –
SGEN
55
DELISTED
Seagen Inc. Common Stock
SGEN
$45.5M 0.5%
+268,000
New +$41.7M
TCDA
56
DELISTED
Tricida, Inc. Common Stock
TCDA
$44.6M 0.49%
9,614,280
– –
TBPH icon
57
Theravance Biopharma
TBPH
$876M
$43.6M 0.48%
5,895,159
+1,331,114
+29% +$14.9M
ALPN
58
DELISTED
Alpine Immune Sciences Inc
ALPN
$43.6M 0.48%
4,081,592
+1,010,637
+33% +$9.31M
MREO
59
Mereo BioPharma
MREO
$50.2M
$41.8M 0.46%
+17,264,764
New +$45.7M
TELA icon
60
TELA Bio
TELA
$30.4M
$41.4M 0.45%
3,027,542
– –
CTKB icon
61
Cytek Biosciences
CTKB
$573M
$41.2M 0.45%
+1,923,139
New +$45.2M
VECT
62
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$39.6M 0.44%
5,123,304
– –
TERN
63
DELISTED
Terns Pharmaceuticals
TERN
$39.5M 0.43%
3,791,204
– –
LOGC
64
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$38.8M 0.43%
8,466,783
– –
DBTX
65
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$38.1M 0.42%
4,945,192
– –
LKFT
66
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$38.1M 0.42%
723,457
+492,552
+213% +$29.2M
APLT
67
DELISTED
Applied Therapeutics
APLT
$37.5M 0.41%
2,257,387
– –
IMA
68
ImageneBio Inc
IMA
$64.2M
$37M 0.41%
244,495
– –
VTGN icon
69
VistaGen Therapeutics
VTGN
$9.73M
$35.4M 0.39%
430,309
-51,953
-11% -$4.51M
CRVS icon
70
Corvus Pharmaceuticals
CRVS
$1.11B
$33.6M 0.37%
6,943,654
-1,109,644
-14% -$3.28M
BNR
71
Burning Rock Biotech
BNR
$96.9M
$33.2M 0.36%
185,620
– –
SRRA
72
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$32.4M 0.36%
1,477,320
– –
SYRE icon
73
Spyre Therapeutics
SYRE
$8.48B
$31.9M 0.35%
160,621
– –
SCPH
74
DELISTED
scPharmaceuticals
SCPH
$31.9M 0.35%
4,797,148
– –
GHRS icon
75
GH Research
GHRS
$1.88B
$31.5M 0.35%
1,428,666
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2021 Portfolio in Review

As of Q3 2021, OrbiMed held 189 positions worth $9.1B, down 8% from $9.89B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q3 2021 filing shows 31 new, 28 increased, 27 reduced and 17 closed positions. Its largest new stake was Invivyd: 5,383,500 shares worth $227M. The largest sale was Aurinia Pharmaceuticals, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology.

  • OrbiMed's largest Q3 2021 buy was Invivyd: 5,383,500 shares worth $227M.
  • OrbiMed added most to Biogen in Q3 2021, an estimated $54.7M increase.
  • OrbiMed's biggest Q3 2021 reduction was Natera, cutting an estimated $55.6M.
  • OrbiMed fully exited Aurinia Pharmaceuticals in Q3 2021, selling an estimated $78.7M.
  • OrbiMed's ten largest holdings make up 30% of its $9.1B portfolio in Q3 2021.
  • OrbiMed opened 31 new positions and closed 17 in Q3 2021.
  • OrbiMed's portfolio value fell 8% quarter-over-quarter to $9.1B.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.